PT920498E - Adn regulador transcricional de ef-1x de hamster - Google Patents

Adn regulador transcricional de ef-1x de hamster

Info

Publication number
PT920498E
PT920498E PT98920128T PT98920128T PT920498E PT 920498 E PT920498 E PT 920498E PT 98920128 T PT98920128 T PT 98920128T PT 98920128 T PT98920128 T PT 98920128T PT 920498 E PT920498 E PT 920498E
Authority
PT
Portugal
Prior art keywords
regulatory dna
hamster
dna transcription
transcription regulator
expression constructs
Prior art date
Application number
PT98920128T
Other languages
English (en)
Inventor
Daniel S Allison
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of PT920498E publication Critical patent/PT920498E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
PT98920128T 1997-05-01 1998-05-01 Adn regulador transcricional de ef-1x de hamster PT920498E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/847,218 US5888809A (en) 1997-05-01 1997-05-01 Hamster EF-1α transcriptional regulatory DNA

Publications (1)

Publication Number Publication Date
PT920498E true PT920498E (pt) 2006-08-31

Family

ID=25300098

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98920128T PT920498E (pt) 1997-05-01 1998-05-01 Adn regulador transcricional de ef-1x de hamster

Country Status (19)

Country Link
US (1) US5888809A (pt)
EP (2) EP0920498B1 (pt)
JP (1) JP2000513948A (pt)
CN (2) CN100430477C (pt)
AT (1) ATE318900T1 (pt)
AU (1) AU742561B2 (pt)
BR (1) BR9804896B1 (pt)
CZ (1) CZ296544B6 (pt)
DE (1) DE69833649T2 (pt)
DK (1) DK0920498T3 (pt)
ES (1) ES2263206T3 (pt)
HU (1) HU225764B1 (pt)
IL (1) IL127897A (pt)
NO (1) NO323853B1 (pt)
PL (1) PL195604B1 (pt)
PT (1) PT920498E (pt)
RU (2) RU2249617C2 (pt)
SK (1) SK285664B6 (pt)
WO (1) WO1998049289A1 (pt)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
KR20000046969A (ko) * 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
AU2002213196A1 (en) * 2000-10-12 2002-04-22 Icos Corporation Modulation of ligand binding/enzymatic activity of alpha beta proteins
AU2002230773A1 (en) * 2000-12-18 2002-07-01 Wyeth Promoters and recombinant expression constructs
ATE466941T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor-aktivität
AU2003243059A1 (en) * 2002-06-14 2003-12-31 Chromagenics B.V. Use of repression blocking sequences in methods for enhancing gene expression
CA2489475C (en) * 2002-06-14 2011-03-29 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
EP1573058B1 (en) * 2002-12-18 2011-09-14 ChromaGenics B.V. A method for improving protein production
ATE354645T1 (de) * 2002-12-20 2007-03-15 Chromagenics Bv Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
US20060172382A1 (en) * 2004-11-08 2006-08-03 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) * 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
EP1809750B1 (en) * 2004-11-08 2012-03-21 ChromaGenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) * 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
EP1819829A1 (en) * 2004-12-08 2007-08-22 ICOS Corporation Recombinant method for making multimeric proteins
AU2005329450A1 (en) * 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
BRPI0617688A2 (pt) * 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
JP5666776B2 (ja) 2005-10-28 2015-02-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 齧歯動物細胞におけるタンパク質発現
EP1969127B8 (en) * 2005-12-21 2017-12-13 Aptevo BioTherapeutics LLC Method of producing biologically active vitamin k dependent proteins by recombinant methods
WO2007081336A1 (en) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Mammalian vectors for high-level expression of recombinant proteins
MX2008013514A (es) 2006-05-17 2008-10-28 Hoffmann La Roche Celulas productoras de polipeptidos.
CA2656558A1 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP1975228A1 (en) 2007-03-28 2008-10-01 Fachhochschule Mannheim Polynucleotides for enhancing expression of a polynucleotide of interest
AU2008245524A1 (en) 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
LT2167540T (lt) * 2007-06-29 2018-04-25 F. Hoffmann-La Roche Ag Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą
JP5642549B2 (ja) 2007-10-12 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 複数の核酸からのタンパク質発現
US7892760B2 (en) 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
WO2009130602A2 (en) 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
CA2771410C (en) 2009-08-06 2020-10-06 Cmc Icos Biologics, Inc. Methods for improving recombinant protein expression comprising reduction in translation efficiency of a selectable marker protein
ES2699718T3 (es) 2009-09-15 2019-02-12 Medlmmune Ltd Células para expresión transitoria y usos de las mismas
WO2011053738A1 (en) 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
EP2339009A1 (en) 2009-12-22 2011-06-29 Sandoz Ag Cold inducible promoter sequences
BR112012024713B1 (pt) 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
EP2753644A1 (en) 2011-09-09 2014-07-16 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
US8609820B2 (en) 2011-10-28 2013-12-17 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
WO2013092720A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
EP2794878B1 (en) 2011-12-22 2020-03-18 F.Hoffmann-La Roche Ag Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
CN107119073A (zh) 2011-12-22 2017-09-01 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
EP3575794A1 (en) 2012-02-10 2019-12-04 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
HK1205188A1 (en) * 2012-02-14 2015-12-11 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
BR112015011462A2 (pt) 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
KR102365484B1 (ko) * 2013-03-12 2022-02-18 에이쥐씨 바이올로직스, 인크. 하이브리드 chef1 프로모터를 이용한 향상된 재조합 단백질 발현
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
RU2535871C1 (ru) * 2013-07-10 2014-12-20 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") Плазмида для экспрессии в клетке китайского хомячка, клетка китайского хомячка - продуцент белка с Gla-доменом и способ получения белка с Gla-доменом
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
EP3071974A2 (en) 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
WO2016039801A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
KR20160131082A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg1-3에 특이적인 항-라미닌4 항체
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
KR102554850B1 (ko) 2015-02-06 2023-07-13 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
EP3283109A1 (en) 2015-04-14 2018-02-21 Boehringer Ingelheim International GmbH Methods of treating diseases
ES2956662T3 (es) 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
EP3560956A3 (en) 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
ES2864211T3 (es) 2016-04-25 2021-10-13 Syntimmune Inc Anticuerpos anti-FcRn humanizados con maduración de la afinidad
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP6818134B2 (ja) 2016-09-29 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド産生細胞を選択するための改善された方法
EP3526252A2 (en) 2016-10-14 2019-08-21 Boehringer Ingelheim International GmbH Methods of treating diseases with il-23a antibody
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
JP2021502955A (ja) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
CN111757730A (zh) 2017-10-06 2020-10-09 普罗塞纳生物科学有限公司 检测甲状腺素运载蛋白的方法
CU20200042A7 (es) 2017-11-29 2021-03-11 Prothena Biosciences Ltd Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
CA3088880A1 (en) 2018-01-10 2019-07-18 Cmc Icos Biologics, Inc. Bidirectional chef1 vectors
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
WO2019235923A1 (en) 2018-06-04 2019-12-12 Erasmus University Medical Center Rotterdam Role for low density lipoprotein receptor-related protein 10 in progressive brain diseases
WO2020006347A1 (en) 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
CN110904127B (zh) 2018-09-18 2024-09-20 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
EP3870604B1 (en) 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
SG11202104549TA (en) 2018-11-08 2021-05-28 Prothena Biosciences Ltd Antibodies recognizing tau
CN119684457A (zh) 2018-11-26 2025-03-25 四十七有限责任公司 针对c-kit的人源化抗体
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
AU2020253685B2 (en) 2019-04-02 2025-09-04 Nykode Therapeutics ASA Immune-stimulatory compositions and use thereof
MX2021013671A (es) 2019-05-09 2021-12-10 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.
TWI877179B (zh) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
US12577297B2 (en) 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
CA3183994A1 (en) 2020-06-24 2021-12-30 Philip James Dolan Iii Antibodies recognizing sortilin
US20240317868A1 (en) 2021-02-05 2024-09-26 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
IL313655A (en) 2021-12-22 2024-08-01 Boehringer Ingelheim Int Anti-C3 antibodies and their antigen-binding fragments and their uses for the treatment of eyes or eye diseases
CN114540352A (zh) * 2022-02-16 2022-05-27 艾瑞生命科学技术(常州)有限公司 一种多核苷酸、载体元件及表达载体和宿主细胞及应用
EP4612180A1 (en) 2022-10-31 2025-09-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
EP4615493A1 (en) 2022-11-08 2025-09-17 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
AU2024342922A1 (en) 2023-09-15 2026-04-23 Othair Prothena Limited Cell penetrating agents and uses thereof
AU2024342899A1 (en) 2023-09-15 2026-04-23 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
AR133828A1 (es) 2023-09-15 2025-11-05 Prothena Biosciences Ltd Anticuerpos anti-tdp-43 y sus usos
TW202525338A (zh) 2023-09-15 2025-07-01 愛爾蘭商普羅希那生物科學有限公司 細胞穿透劑及其用途
WO2026029677A1 (en) 2024-08-02 2026-02-05 Erasmus University Medical Center Rotterdam Co-stimulatory t-cell receptor to treat patient with tumor or immune-related disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508442D0 (en) * 1985-04-01 1985-05-09 Celltech Ltd Expression vector
JP3051411B2 (ja) * 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
RU2128227C1 (ru) * 1989-12-22 1999-03-27 Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) Способ активации транскрипционно-молчащего гена
US5650294A (en) * 1990-06-25 1997-07-22 Basf Aktiengesellschaft Isolated promoter and terminator of elongation factor 1-α
AU664847B2 (en) * 1991-05-15 1995-12-07 Cell Genesys, Inc. Genomic modifications with homologous DNA targeting
CA2051085C (en) * 1991-09-10 2001-08-21 Shigekazu Nagata Expression plasmids
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery

Also Published As

Publication number Publication date
CZ296544B6 (cs) 2006-04-12
EP0920498B1 (en) 2006-03-01
CN100430477C (zh) 2008-11-05
ATE318900T1 (de) 2006-03-15
BR9804896A (pt) 1999-08-31
NO323853B1 (no) 2007-07-16
AU742561B2 (en) 2002-01-03
EP1676916A1 (en) 2006-07-05
NO990025L (no) 1999-03-01
EP0920498A1 (en) 1999-06-09
RU2004136574A (ru) 2006-05-27
US5888809A (en) 1999-03-30
IL127897A (en) 2005-12-18
ES2263206T3 (es) 2006-12-01
SK11899A3 (en) 2000-05-16
JP2000513948A (ja) 2000-10-24
CZ28099A3 (cs) 2000-02-16
PL195604B1 (pl) 2007-10-31
NO990025D0 (no) 1999-01-04
RU2249617C2 (ru) 2005-04-10
DE69833649T2 (de) 2006-12-28
HUP0004137A3 (en) 2003-08-28
DK0920498T3 (da) 2006-07-10
HK1022719A1 (en) 2000-08-18
WO1998049289A1 (en) 1998-11-05
BR9804896B1 (pt) 2013-11-26
HU225764B1 (en) 2007-08-28
CN1230991A (zh) 1999-10-06
SK285664B6 (sk) 2007-05-03
IL127897A0 (en) 1999-11-30
HUP0004137A2 (en) 2001-03-28
DE69833649D1 (de) 2006-04-27
AU7277098A (en) 1998-11-24
PL331005A1 (en) 1999-06-21
CN101570753A (zh) 2009-11-04

Similar Documents

Publication Publication Date Title
PT920498E (pt) Adn regulador transcricional de ef-1x de hamster
ATE373672T1 (de) Synthese von methoxynukleoside und enzymatische nukleisäure moleküle
ATE342911T1 (de) Synthese von nukleosiden und polynukleotiden
DK1100880T3 (da) Urat oxidase
ATE319854T1 (de) Enzymaktive dna moleküle
DE69333731D1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
DE69533564D1 (de) Effektor-Proteine für Rapamycin
ATE376591T1 (de) Neisseria meningitidis antigene und zusammenstellungen
DE69524740D1 (de) Thymidin-kinase-mutanten
DK0960192T3 (da) Syntetiske polynukleotider
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
DK1235916T3 (da) Isolerede polynukleotider med et formindsket indhold af 5'CpG3' epigenitiske kontrolmotiver og anvendelser deraf
DE69934017D1 (de) 2,6-beta-d-fruktanhydrolase enzym und verfahren zu dessen verwendung
DE69809930D1 (de) Isolierung und verwendung von nukleinsäuremolekülen, welche für mitglieder der ssx-familie kodieren
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
ATE296835T1 (de) Orotidin-5'-phosphatdecarboxylase-gen, genkonstrukt enthaltend dieses gen und seine verwendung
CA2259145A1 (en) Hamster ef-1.alpha. transcriptional regulatory dna
DE69925927D1 (de) Mutmassliches 98 kd protein des aussenmembrans von chlamydia und dafür kodierende dns sowie deren verwendung
ATE257862T1 (de) Verwendung von calculus